A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)
Status:
Completed
Trial end date:
2018-11-21
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 milligrams
(mg) compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major
depressive disorder (MDD) who have a partial response to ADT.
Phase:
Phase 3
Details
Lead Sponsor:
Allergan Naurex, Inc, an affiliate of Allergan plc